Abstract:Background: International consensus recognises four medulloblastoma molecular subgroups: WNT (MBWNT), SHH (MBSHH), group 3 (MBGrp3), and group 4 (MBGrp4), each defined by their characteristic genome-wide transcriptomic and DNA methylomic profiles. These subgroups have distinct clinicopathological and molecular features, and underpin current disease subclassification and initial subgroup-directed therapies that are underway in clinical trials. However, substantial biological heterogeneity and differences in survival are apparent within each subgroup, which remain to be resolved. We aimed to investigate whether additional molecular subgroups exist within childhood medulloblastoma and whether these could be used to improve disease subclassification and prognosis predictions. Methods: In this retrospective cohort study, we assessed 428 primary medulloblastoma samples collected from UK Children's Cancer and Leukaemia Group (CCLG) treatment centres (UK), collaborating European institutions, and the UKCCSG-SIOP-PNET3 European clinical trial. An independent validation cohort (n=276) of archival tumour samples was also analysed. We analysed samples from patients with childhood medulloblastoma who were aged 0-16 years at diagnosis, and had central review of pathology and comprehensive clinical data. We did comprehensive molecular profiling, including DNA methylation microarray analysis, and did unsupervised class discovery of test and validation cohorts to identify consensus primary molecular subgroups and characterise their clinical and biological significance. We modelled survival of patients aged 3-16 years in patients (n=215) who had craniospinal irradiation and had been treated with a curative intent. Findings: Seven robust and reproducible primary molecular subgroups of childhood medulloblastoma were identified. MBWNT remained unchanged and each remaining consensus subgroup was split in two. MBSHH was split into age-dependent subgroups corresponding to infant (<4·3 years; MBSHH-Infant; n=65) and childhood patients (≥4·3 years; MBSHH-Child; n=38). MBGrp3 and MBGrp4 were each split into high-risk (MBGrp3-HR [n=65] and MBGrp4-HR [n=85]) and low-risk (MBGrp3-LR [n=50] and MBGrp4-LR [n=73]) subgroups. These biological subgroups were validated in the independent cohort. We identified features of the seven subgroups that were predictive of outcome. Cross-validated subgroup-dependent survival models, incorporating these novel subgroups along with secondary clinicopathological and molecular features and established disease risk-factors, outperformed existing disease risk-stratification schemes. These subgroup-dependent models stratified patients into four clinical risk groups for 5-year progression-free survival: favourable risk (54 [25%] of 215 patients; 91% survival [95% CI 82-100]); standard risk (50 [23%] patients; 81% survival [70-94]); high-risk (82 [38%] patients; 42% survival [31-56]); and very high-risk (29 [13%] patients; 28% survival [14-56]). Interpretation: The discovery of seven novel, clinically significant subgroups improves disease risk-stratification and could inform treatment decisions. These data provide a new foundation for future research and clinical investigations. Funding: Cancer Research UK, The Tom Grahame Trust, Star for Harris, Action Medical Research, SPARKS, The JGW Patterson Foundation, The INSTINCT network (co-funded by The Brain Tumour Charity, Great Ormond Street Children's Charity, and Children with Cancer UK).

A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience.

Molecular Subgroups of Adult Medulloblastoma: a Long-Term Single-Institution Study.

MEDB-05. Survival and prognostic factors in childhood medulloblastoma: A China single center experience from 2006 to 2015

Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy

Subgroup-Specific Diagnostic, Prognostic, and Predictive Markers Influencing Pediatric Medulloblastoma Treatment

Analysis of the Personalized Treatment and the Relevant Prognostic Factors in Children with Medulloblastoma

Differences in the Prognostic Value of Tumor Extent of Resection among the Molecular Subgroups of Medulloblastoma: A Single Centre Study of 113 Cases

Medulloblastoma: Molecular understanding, treatment evolution, and new developments

Risk Factors for the Prognosis of Pediatric Medulloblastoma: a Retrospective Analysis of 40 Cases

[RETRACTED ARTICLE] Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases

Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study

Impact of tumor location and fourth ventricle infiltration in medulloblastoma

Clinical Outcomes of Adult Medulloblastoma: A Retrospective Analysis at a Single Institute

Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia

A New Perspective for the Study of Medulloblastoma

Treatment Barriers and Clinical Outcome of Children with Medulloblastoma in China: a Report from the Chinese Children's Cancer Group (CCCG).

Factors Affecting the Prognosis of Children with Medulloblastoma: A Single Institution Retrospective Analysis of 40 Cases

Clinical and effect analyses of comprehensive treatment for medulloblastoma: a report of 115 children

Clinical Characterization of Adult Medulloblastoma and the Effect of First-Line Therapies on Outcome; the MD Anderson Cancer Center Experience

Application of Individualized Therapy Based on Molecular Classification in the Treatment of Medulloblastoma in Children

[Analysis of Pathologic Characteristics and Prognosis in Different Subtypes of Adult Medulloblastoma].